Acute undifferentiated leukaemia with undifferentiated myeloid sarcoma: case report and literature review

DOI: https://doi.org/10.21203/rs.3.rs-1374944/v1

Abstract

Background: With the advancement of diagnostic technology, true acute undifferentiated leukaemia is becoming more rare, and acute undifferentiated leukaemia with extramedullary sarcoma has not been reported.

Case presentation: This article reports a case of acute undifferentiated leukaemia with extramedullary sarcoma. Flow cytometric analysis of the bone marrow and lymph nodes indicated that the tumour cells of both were of the same origin and mainly expressed stem cell markers and CD7, no myeloid-specific markers, T-lymphoblastic-related markers, and B-lymphoblastic-related markers. Although the priming regimen combined with azacitidine was ineffective, complete remission was achieved by switching to azacitidine combined with HIA (homoharringtonine, idarubicin plus Ara-C).

Conclusions: To diagnosis de novo acute leukemia with extensive and comprehensive cellular immune maker detection is available and credible, the expression of a single relatively non-specific myeloid antigen as a immune maker to detect AUL or AUL associated with sarcoma is precise and effective in our case, which patient was benefit from HIA regiment.

The Novelty Statements

To the best of our knowledge this is the first reported case of acute undifferentiated leukaemia with undifferentiated myeloid sarcoma and successfully treated by HIA regimen. We found to diagnose acute undifferentiated leukaemia extensive and comprehensive cellular immune maker detection is mandatory and extramedullary involvement was best detected by FCM.

Background

Acute undifferentiated leukaemia (AUL) is a rare type of acute leukaemia characterized by the absence of lineage-specific differentiation antigens and loss of myeloid antigen expression, with a low incidence rate and poor prognosis(1). Myeloid sarcoma, a special type of myeloid tumour that manifests as soft tissue masses rather than bone marrow involvement, can occur alone or accompanied by acute myeloid leukaemia (AML). The most commonly involved sites are the orbits and lymph nodes, also called chloroma. There are few reports of undifferentiated myeloid sarcoma, and because specific antigens are rarely expressed, it is easily confused with histiocyte tumours. Acute undifferentiated leukaemia is rare owing to its clinical features, primarily bone marrow involvement, and cases accompanied by extramedullary sarcoma have not been reported. Here, we describe a case of acute undifferentiated leukaemia with undifferentiated myeloid sarcoma and present a review of the literature.

Case Presentation

A 23-year-old male patient visited our hospital on October 11, 2020. His chief complaint was cough for 4 months with fever. Antibiotic treatment was ineffective. His medical history was unremarkable. Physical examination showed signs of anaemia; the bilateral submandibular and left axillary lymph nodes were palpable, the right submandibular lymph node was 1.5 cm × 1.5 cm, and the left submandibular lymph node was 4 cm × 4 cm. No organomegaly was observed. CBC revealed a white blood cell count of 3.670 × 109/L, neutrophil count of 1.402 × 109/L, haemoglobin 44 g/L, platelet count of 437 × 109/L, and 7.5% immature cells. Biochemistry tests showed LDH 559 U/L, and coagulation function tests were normal. Based on bone marrow aspiration from the left posterior superior iliac spine, proliferation of nucleated cells in the bone marrow was active, with a granulocyte to erythrocyte ratio of 0.50:1. The proportion of blasts was increased, accounting for 16.0% of ANC (figure 1). Flow cytometry (FCM) analysis of the bone marrow was performed; 50,000 cells were obtained and analysed. In a CD45/SSC scatter plot, 28.23% of immature cells with an abnormal immunophenotype were detected in the CD45 dim and SS low area. CD34, CD33 and CD38 were positive. CD7 and HLA-DR were partially positive, and CD56 was dim. CD2, CD19, CD20, CD10, CD13, CD117, CD15, CD14, MPO, cCD79a and cCD3 were negative (figure 2). A diagnosis of myelodysplastic syndrome with excess blast 2 (MDS-EB2) was made, and azacytidine 100 mg qd on days 1 to 7 plus a 14-days priming regimen (G-CSF 300 µg qd d2–17, homoharringtonine 1 mg qd d3–17, cytarabine 15 mg bid d3–17) was started. As lymph node enlargement in MDS is rare, we performed another bone marrow test and lymph node biopsy. Bone marrow aspiration from the right posterior superior iliac spine on the 12th day of induction chemotherapy showed that blasts accounted for 24.5% of ANCs, which met the criteria for acute leukaemia. FCM was consistent with the previous immunophenotype of bone marrow blasts. Karyotype results were 90~91<4n>, XXYY, add(2)(q37)×2, 6, i(17)(q10)×2[6]/46,XY[14]. A somatic frameshift mutation, c.1236dup (p. Gln413Thrfster13), in the ETV6 gene was detected in the bone marrow sample. FCM of the left cervical lymph node sample showed 36.4% immature cells with an abnormal immunophenotype in CD45 dim/low SS areas expressing CD34, CD33 and CD7 but not CD2, CD10, CD5, CD4, CD8 and CD117. Immunohistochemistry of immature cells in the left cervical lymph node showed the following: CD7 (+), CD43(+), CD3(-), CD2(-), CD5(-), CD4(-), CD8(-), CD10(+), CD34(+), CD99(+), TdT(-), CD20(-), PAX-5(-), CD15(-), MPO(-), CD21(-), CD117(-), CD123(-), PGM-1(-), KP1(-), CK(-), and Ki-67 90% (figure 3). The EBER1/2 in situ hybridization result was tumour cells (-). Therefore, a diagnosis of acute undifferentiated leukaemia with undifferentiated granulocytic sarcoma was considered. The chemotherapy plan was changed to the HIA regimen (homoharringtonine 3 mg d1-3, idarubicin 10 mg d1-3, cytarabine 1.5 g q12 h d1-3) due to the high blasts in bone marrow after 12 days of chemotherapy, and the patient achieved complete remission after the regimen was changed. After CR, the patient was scheduled for consolidation chemotherapy and stem cell transplantation. Unfortunately, he died of sepsis due to myelosuppression after a scheduled 2nd consolidation chemotherapy cycle.

Discussion And Conclusions

This patient was a rare case of AUL accompanied by lymph node masses. Lymph node flow cytometric analysis showed that the immunophenotype of lymph node tumour cells was consistent with the immunophenotype of leukaemia cells from his bone marrow, which was consistent with AUL. According to biopsy, the lymph node structure was destroyed, and immunohistochemistry showed that the tumour cells of the lymph nodes and bone marrow were identical and consistent with AUL. Therefore, this case was in line with a diagnosis of AUL with extramedullary sarcoma. We conducted a literature search, and to the best of our knowledge, this is the first report of AUL with extramedullary sarcoma.

AUL belongs to acute leukaemias of ambiguous lineage (ALAL) and is characterized by lack of lineage-specific antigens in leukaemia cells and expression of no or only one myeloid leukaemia-related immune marker(2). This type of leukaemia is extremely rare. A total of 1888 AUL cases diagnosed from 2000 to 2016 are found in the US SEER database, with an incidence rate of approximately 1.34 persons/million(2). With the advancement of diagnostic technology, the number of true AUL cases has been decreasing yearly(2). Patients with AUL are often older, with a median age of 75 years, and 70% of patients are over 60 years old. Compared with other AMLs, AUL has a worse prognosis, and the median survival time is significantly shorter than that of AML(3). The diagnosis of AUL mainly relies on bone marrow flow cytometry to analyse immune markers of leukaemia cells(3). The WHO defines AUL as a leukaemia that expresses neither lymphoid markers nor myeloid markers and for which NK-cell precursors, basophils, and even nonhaematopoietic tumours need to be excluded. Weinberg et al. reported 24 cases of AUL, with no significant difference from AML-M0 in terms of age of onset, blood cell count, degree of bone marrow hyperplasia, and ratio of bone marrow blasts(3). In terms of immunophenotype, myeloid markers, including CD13, CD33, and CD117, were not expressed in 6 cases; in 15 cases, 1 myeloid marker was partially or completely expressed, and 1 myeloid marker plus another myeloid marker were partially or weakly expressed in 3 cases. In our case, blasts from both the bone marrow and lymph nodes expressed only one myeloid marker, CD33. In Weinberg's study, B cell markers such as CD19, CD20, and CD10 were not expressed in 24 cases of AUL, but in 5 cases, cytosolic CD22 or cytosolic CD79a was partially expressed(3). No case expressed cCD3 or sCD3, but expression of other T cell-related antigens was common, with CD7 being the most common. In AUL, blasts rarely express more than one monocyte marker; two cases expressed CD11b, and only one case was partially positive for nonspecific esterase. The blasts in our patient expressed CD7 but were negative for sCD3 and cCD3, and no monocyte marker was positive.

AML with minimal differentiation, also known as AML-M0, is a more common AML subtype with no morphological or cytochemical evidence of myeloid differentiation and can easily be confused with AUL. Myeloid maturation of blasts in AML-M0 is demonstrated by immunological markers. The most vital myeloid marker, MPO, is often negative by cytochemistry but may be positive in some blasts by flow cytometry or immunohistochemistry. Blasts of AML-M0 express at least two myeloid-associated markers, usually CD13, CD117, and CD33. CD7 expression is reported in approximately 40% of AML-M0 cases. In 2016, the WHO noted that expression of a single, relatively nonspecific myeloid-associated antigen, especially by only some blasts and along with other markers of primitive cells (e.g., CD7, CD34, and HLA-DR), is more typical of AUL than AML-M0. There is still another subtype of leukaemia that may be confused with AUL-acute leukaemia of ambiguous lineage, not otherwise specified (NOS) in which combinations of markers that do not allow for their classification as AUL are expressed. In AUL, no more than one membrane marker for any given lineage is typically expressed. Hence, if a given lineage expresses more than one marker, a diagnosis of acute leukaemias of ambiguous lineage, NOS, would be appropriate.

Myeloid sarcoma is a type of myeloid neoplasm in which myeloid tumour cells invade the extramedullary tissues and destroy the original tissue structure to form a mass(4). It can occur independently of AML, concomitantly with AML, and after bone marrow remission(5). Myeloid sarcoma is common in AML-M0, AML-M4 and AML-M5. Myeloid sarcoma can affect any site of the body, most often involving the skin, lymph nodes, gastrointestinal tract, bone, soft tissue and testes(6). Myeloid sarcoma usually expresses myeloid tumour-related markers, though undifferentiated myeloid sarcoma is rarely seen. In 1995, Tosi et al. reported a case of epidural undifferentiated granulocytic sarcoma that occurred before acute promyelocytic leukaemia, which was cured by treatment with all-trans retinoic acid, but the case was not truly undifferentiated due to a lack of flow cytometry immunophenotyping(7). In our case, lymph node puncture and flow cytometry and immunohistochemistry were performed. Flow cytometry confirmed that tumour cells from the lymph nodes had the same immunophenotype as leukaemia cells from the bone marrow, indicating that the tumour cells from the lymph nodes were the same as the leukaemia cells from the bone marrow of this patient. Immunohistochemistry results were also consistent with FCM results. Combined with the bone marrow immunophenotype, this case was consistent with acute undifferentiated leukaemia, indicating undifferentiated myeloid sarcoma in the affected lymph nodes.

Abbreviations

Acute undifferentiated leukaemia: AUL; Flow cytometry: FCM; acute leukaemias of ambiguous lineage: ALAL; acute myeloid leukaemia: AML; myelodysplastic syndrome with excess blast 2: MDS-EB2; not otherwise specified: NOS

Declarations

Ethics approval and consent to participate

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted/waived by the Ethics Committee of Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital (No. 240 of year 2020).

Consent for publication

A written informed consent form was signed by the patient. All information of the patient is anonymized and the submission does not include images that may identify the person.

Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request..

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by Tao Jiang’s Health Commission of Sichuan Province (Grant No. 202055031103) , Commission of the Cardre Health Care in Sichuan Province (Grant No. 2017-228). And the fundings of Ling Zhong were: the National Natural Science Foundation of China (82002212), the Science & Technology Department of Sichuan Province (19YJ0593),  the Sichuan Provincial People's Hospital (2018LY03), the Chengdu Science and Technology Bureau (2019-YF05- 00572-SN), the China Postdoctoral Science Foundation Grant (2019M663567),  the fundation of Basic scientific research in Central Universities of University of Electronic Science and technology (ZYGX2020J024).

Authors' contributions

TJ write case presentation and discussion of the manuscript. XqW invested the biopsy of bone marrow and lymph node and write the manuscript accordingly. LL and SZ searched online documents and write the manuscript accordingly. YH examined bone marrow aspiration samples and write the manuscript accordingly. QX performed FCM analysis and write the manuscript accordingly. JC and LZ initiated the work and provided the case and made vital editing for the manuscript.

Acknowledgements

Not applicable.

References

  1. Kurzer JH, Weinberg OK. Acute Leukemias of Ambiguous Lineage: Clarification on Lineage Specificity. Surg Pathol Clin. 2019 Sep;12(3):687–97.
  2. Qasrawi A, Gomes V, Chacko CA, Mansour A, Kesler M, Arora R, et al. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. Leuk Res. 2020 Feb;89:106301.
  3. Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, et al. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol Off J U S Can Acad Pathol Inc. 2019 Sep;32(9):1373–85.
  4. Horny HP, Kaiserling E, Sillaber C, Walchshofer S, Valent P. Bone marrow mastocytosis associated with an undifferentiated extramedullary tumor of hemopoietic origin. Arch Pathol Lab Med. 1997 Apr;121(4):423–6.
  5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009/04/10 ed. 2009 Jul 30;114(5):937–51.
  6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016/04/14 ed. 2016 May 19;127(20):2391–405.
  7. Tosi A, De Paoli A, Fava S, Luoni M, Sironi M, Tocci A, et al. Undifferentiated granulocytic sarcoma: a case with epidural onset preceding acute promyelocytic leukemia. Haematologica. 1995 Feb;80(1):44–6.